Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. announced the grant of 74,000 options under its Post-IPO Share Option Scheme and 234,800 awards under its Pre-IPO ESOP on October 2, 2025. These grants are part of the company’s strategy to attract, retain, and incentivize employees, aligning with its remuneration policy to enhance operational efficiency. The options have a seven-year exercise period with a vesting schedule over four years, and they do not include performance targets, which the Remuneration Committee considers competitive and consistent with the company’s objectives.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of transformative pharmaceutical products. The company aims to address critical unmet medical needs in the Asian market, particularly in the fields of oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 6,367,522
Technical Sentiment Signal: Buy
Current Market Cap: HK$19.9B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.